The present invention also relates to a, preferably solid, pharmaceutical composition comprising trimegestone in a quantity of more than 500 ??g, preferably at least 600 ??g, still more preferably at least 700 ??g, most preferably at least 1,000 ??g and in particular at least 1,200 ??g, in combination with ethinyloestradiol, preferably in a quantity of 20??5 ??g.